학술논문
Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study
Document Type
article
Author
Allison M. Bock; Jennifer J. Gile; Melissa C. Larson; Kittika Poonsombudlert; Reema K. Tawfiq; Seth Maliske; Matthew J. Maurer; Brian F. Kabat; Jonas Paludo; David J. Inwards; Sabarish Ayyappan; Brian K. Link; Stephen M. Ansell; Thomas M. Habermann; Thomas E. Witzig; Grzegorz S. Nowakowski; James R. Cerhan; Umar Farooq; Yucai Wang
Source
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Subject
Language
English
ISSN
2044-5385
Abstract
Abstract Over the last two decades, the frontline therapy for mantle cell lymphoma (MCL) has evolved. However, the impact of subsequent lines of therapy on survival outcomes has not been well characterized. In this study, we investigated the treatment patterns and survival outcomes in patients with relapsed/refractory (R/R) MCL treated with second-line (2 L) therapy. Adult patients with newly diagnosed MCL from 2002 to 2015 were enrolled in a prospective cohort study. Clinical characteristics, 2 L treatment details, and outcomes were compared between patients who received 2 L treatment between 2003–2009 (Era 1), 2010–2014 (Era 2), and 2015–2021 (Era 3). 2 L treatment was heterogenous in all eras, and there was a substantial shift in the pattern of 2 L therapy over time. The estimated 2-year EFS rate was 21% (95% CI, 13–35), 40% (95% CI, 30–53), and 51% (95% CI, 37–68) in Era 1–3 respectively, and the 5-year OS rate was 31% (95% CI, 21–45), 37% (95% CI, 27–50), and 67% (95% CI, 54–83) in Era 1–3, respectively. These results provide real-world evidence on evolving treatment patterns of 2 L therapy based on the era of relapse. The changes in 2 L treatment correlated with improved EFS and OS, suggesting that treatment advances are associated with improved outcomes in patients with R/R MCL.